Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Radioiodine Ablation of Postsurgical Thyroid Remnants After Treatment With Recombinant Human TSH (rhTSH) in Patients With Moderate-to-Severe Graves’ Orbitopathy (GO): A Prospective, Randomized, Single-Blind Clinical Trial
source: The Journal of Clinical Endocrinology and Metabolism
authors: Moleti M, Violi MA, Montanini D, Trombetta C, Di Bella B, Sturniolo G, Presti S, Alibrandi A, Campennì A, Baldari S, Trimarchi F, Vermiglio Fsummary/abstract:
Recent evidence suggests thyroidectomy (Tx) followed by radioiodine remnant ablation to be beneficial to Graves’ orbitopathy (GO) patients.
The aim of the study was to evaluate the effect of 131I thyroid ablation after recombinant human TSH stimulation in patients with moderate-to-severe GO.
Design, Patients, and Interventions:
The study was prospective, randomized, and single-blind, and it included 40 consecutive patients with moderate-to-severe GO randomized into: 1) a Tx-radioactive iodine (RAI) group (20 subjects who underwent total-Tx and 131I ablation after recombinant human TSH stimulation); and 2) a Tx group (20 subjects who underwent total-Tx alone).
The overall GO outcome 12 months after Tx/radioiodine ablation was the main measure.
GO evaluation at the end of iv glucocorticoids showed eye disease to be improved in 65% of the Tx-RAI group and 60% of the Tx group patients. At 6 and 12 months, no further changes in the GO outcome could be observed in the Tx-RAI group. Conversely, five patients from the Tx group exhibited a deterioration in GO. At 12 months, GO was found to be improved in 70% of the Tx-RAI and 20% of the Tx group patients, the latter being found to be stable (55%) or worse (25%) than at baseline evaluation. At 12 months, GO was found to be inactive in a significantly higher percentage of patients in the Tx-RAI than in the Tx group (75 vs 30%; P < .01).
Postoperative radioiodine ablation proved more effective than Tx alone in inducing earlier and steadier GO improvement in patients with moderate-to-severe GO treated with iv glucocorticoids over a 24-month follow-up period.
read more full text
Anatomic Considerations in Thyroid Eye DiseasePurpose: To review and summarize the cl...
Victor Maurice Elner, MD, PhDVictor Maurice Elner is a Professor of o...
Graves’ Eye DiseaseWhat is the Thyroid Gland? The thyroid ...
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of LifeHorizon Therapeutics plc today announced...
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
ENFOQUE en la salud ocularhttps://www.onegravesvoice.com/wp-conten...
Quality of Life and Neuropsychiatric Disorders in Patients With Graves’ Orbitopathy: Current ConceptsGraves' disease (GD) is an autoimmune ch...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.